HER2 inhibitors

Pertuzumab - Trastuzumab - Trastuzumab emtansine      

Select            
Trial Studied trt Control trt patientstagsROB Trial result

advanced breast cancer (metastatic)

pertuzumab
CLEOPATRA, 2012          NCTpertuzumab + trastuzumab +docetaxeltrastuzumab + docetaxel 1st line HER-2 positive Low risk of bias suggesting
neoSphere (Group B), 2012      NCTpertuzumab + trastuzumab +docetaxeltrastuzumab + docetaxel HER-2 positive Exploratory -
trastuzumab
TAnDEM (Kaufman), 2009   trastuzumab + anastrozoleanastrozole alone HER-2 positive HR positive -
von Minckwitz, 2009   trastuzumab + capecitabinecapecitabine alone HER-2 positive previously treated by HER-2 antibody trastuzumab failure -
Marty, 2005   trastuzumab + docetaxeldocetaxel alone 1st line HER-2 positive -
Blackwell, 2010   trastuzumab + lapatiniblapatinib alone ErbB2 positive previously treated by HER-2 antibody trastuzumab failure -
Huober, 2012   trastuzumab + letrozoleletrozole alone HER-2 positive HR positive -
Gasparini, 2006   trastuzumab + paclitaxelpaclitaxel alone HER-2 positive -
Slamon, 2001   trastuzumab + standard chemotherapystandard chemotherapy alone HER-2 positive -
trastuzumab emtansine
EMILIA, 2012      NCTtrastuzumab emtansinelapatinib plus capecitabine 2nd line HER-2 positive previously treated by HER-2 antibody previously treated by taxanes suggesting
TH3RESA, 2014    NCTtrastuzumab emtansineusual care 2nd+ line HER-2 positive previously treated by HER-2 antibody Risk of bias suggesting

early breast cancer

pertuzumab
Aphinity    NCTpertuzumabplaceboLow risk of bias -
trastuzumab
NSABP B31, 2005   trastuzumabcontrolsuggesting
BCIRG006, 2013   trastuzumabcontrolsuggesting
Buzdar, 2005   trastuzumabcontrolsuggesting
FinHer, 2006   trastuzumabcontrolnegative
HERA, 2005   trastuzumabcontrolsuggesting
N9831, 2005   trastuzumabcontrolsuggesting
NOAH, 2010   trastuzumabcontrolnegative
PACS-04, 2009   trastuzumabcontrolsuggesting
N9831 (1)   trastuzumabcontrolsuggesting
N9831 (2)   trastuzumabcontrolsuggesting
FinHer (1)   trastuzumabcontrolnegative